(CLX) The Clorox Company Company Overview

What does The Clorox Company do?

The Clorox Company is a consumer staples manufacturer built around household and professional cleaning, disinfecting, food, filtration, cat litter, grilling, bags and wraps, personal care, and international home-care brands. Its common stock trades under ticker CLX on the New York Stock Exchange, and its filings describe a portfolio that reaches mass retailers, grocery chains, warehouse clubs, dollar stores, e-commerce channels, distributors, and professional buyers. The company’s FY2025 Form 10-K reported $7.104B of net sales, about 7,600 employees, operations in about 25 countries and territories, and product sales in approximately 100 markets.

What are the main products and customers?

Clorox is not a single-brand bleach company anymore. The portfolio includes Clorox bleach, wipes and disinfecting products; Pine-Sol, Tilex, Liquid-Plumr and Formula 409; CloroxPro and Clorox Healthcare; Glad bags and wraps; Fresh Step and Scoop Away cat litter; Kingsford charcoal; Hidden Valley food products; Brita water filtration; and Burt’s Bees personal care. The official company site frames the business around trusted everyday brands and health, wellness, and household usefulness rather than a single product line, which helps explain why Clorox is often studied as a brand portfolio and category-management case, not only as a cleaning-products company. The company’s own description of its brands and purpose is available through its official company website.

Why does customer concentration matter?

The business is scale retail-driven. U.S. markets generated 86% of FY2025 net sales. Walmart Inc. and its affiliates accounted for 27% of consolidated FY2025 net sales, while the five largest customers represented nearly half of sales. That concentration can improve distribution efficiency and shelf visibility, but it also gives large retailers bargaining power. For a student or investor, this is the first strategic trade-off: Clorox’s brands have high household recognition, but a large share of the company’s volume still passes through a small number of powerful retail customers.

How does Clorox make money?

Clorox makes money by selling branded consumable products through retail and professional channels. The model is mostly product revenue, not subscription revenue: the company earns gross profit when consumers, institutions, or distributors buy bleach, wipes, trash bags, cat litter, charcoal, dressings, filters, personal care products, or professional hygiene products. The analytical question is therefore not user growth or recurring software retention; it is whether the company can hold volume, price, shelf space, and margins while funding advertising, innovation, distribution, and manufacturing resilience.

How do gross margin and brand spending connect?

In the FY2025 annual report materials, Clorox reported gross profit of $3.213B and gross margin of 45.2%, up 220 basis points from FY2024. It also spent $770M on advertising and sales promotion, equal to 10.8% of sales, and $121M on research and development, equal to 1.7% of sales. Those figures show the economic loop: branded categories can produce attractive gross margins, but the moat requires continual spending to defend awareness, shelf velocity, claims, packaging and innovation.

Which segments and brands matter most?

Clorox reports four segments: Health and Wellness, Household, Lifestyle and International. Health and Wellness includes U.S. cleaning, disinfecting and professional products. Household includes bags and wraps, cat litter and grilling. Lifestyle includes food, water filtration and natural personal care. International includes home care, bags and wraps, cat litter and filtration products sold outside the United States. The annual segment structure is important because it shows that Clorox’s valuation is not tied to one narrow category; it is tied to a portfolio of small-to-mid-sized categories where brand rank and distribution matter.

Which product lines explain the mix?

Why is Health and Wellness the strategic anchor?

Health and Wellness generated $840M of FY2025 adjusted EBIT, more than half of reportable segment adjusted EBIT before Corporate and Other. It also produced 9% sales growth and 17% adjusted EBIT growth in FY2025, helped by volume recovery after earlier operating disruption. That makes it the clearest bridge between Clorox’s historical cleaning identity and its newer professional hygiene ambitions.

What does Clorox’s latest reported period show?

The latest official quarter in the available reporting package is Q3 FY2026, the quarter ended March 31, 2026. Clorox reported net sales of $1.670B, essentially flat versus $1.668B in the prior-year quarter, while organic sales declined 1%. The Q3 FY2026 earnings release shows a mixed picture: flat sales, lower gross margin, disciplined operating expense, higher adjusted EPS, and a cash-flow drag from the Glad joint venture termination payment.

What changed by segment in Q3 FY2026?

How should the quarter be interpreted?

The quarter was not a clean growth story. Household grew 3% and International grew 8%, helped by foreign exchange, while Lifestyle declined 9%. Health and Wellness was flat but still generated $158M of adjusted EBIT. Management’s FY2026 outlook also warned that reported net sales were expected to decline about 6%, with organic sales down about 9%, including a negative 7.5-point impact from the reversal of incremental shipments taken during the ERP transition period.

How financially strong is Clorox after ERP, Glad and GOJO?

Clorox’s financial profile is brand-rich but transition-heavy. FY2025 free cash flow was strong, but the March 2026 balance sheet was temporarily reshaped by pre-funding for the GOJO acquisition and the Glad joint venture termination payment. The Q3 FY2026 Form 10-Q reported $1.187B of cash and cash equivalents at March 31, 2026, compared with $167M at June 30, 2025, but also $1.591B of notes and loans payable and $2.487B of long-term debt.

What does the balance sheet show?

How does Clorox allocate cash?

The forward issue is not whether Clorox can generate cash in normal conditions; FY2025 showed that it can. The issue is sequencing. During the nine months ended March 31, 2026, operating cash flow was $282M, down 59%, primarily because of the Glad venture termination payment. In the same nine-month period, Clorox paid $452M of dividends and repurchased $254M of shares. That combination makes deleveraging capacity, dividend coverage and GOJO synergy realization central monitoring points.

What strategic history explains Clorox today?

Clorox’s history matters because the present company is a layered portfolio built from an original bleach and disinfecting franchise, decades of brand extensions, category acquisitions, and recent portfolio cleanup. The official company timeline shows the early arc from industrial bleach to household brand, while recent filings show a shift toward sharper focus, digital operating systems and professional hygiene.

1. 1913-1914
   The company began in Oakland and launched industrial-strength bleach, then registered the Clorox brand and diamond trademark. The origin still explains the brand’s association with cleaning and efficacy.
2. 1916
   Management pushed Clorox toward household use, turning a chemical product into a consumer staple and establishing the repeat-purchase logic that still defines the model.
3. 1928
   The company reorganized and went public with 200,000 shares, supporting national distribution and a broader consumer brand identity.
4. 2022-2026
   A multi-year digital transformation replaced core ERP and cloud platforms. The program cost roughly $580M of incremental investment and was completed in Q3 FY2026, but it also created shipment and inventory timing effects.
5. 2024-2025
   Clorox divested Better Health Vitamins, Minerals and Supplements and recorded a $118M loss on divestiture in FY2025, signaling tighter focus on core categories.
6. 2026
   Clorox completed the GOJO acquisition after the end of Q3 FY2026, adding Purell and a professional hygiene platform that changes the Health and Wellness growth narrative.

How did the turning points change the business model?

The consistent thread is trust-based repeat purchase. Early product efficacy created the original cleaning brand; public-market scale and national distribution made the brand commercially durable; category expansion reduced dependence on bleach alone; digital investment aimed to modernize ordering, inventory and analytics; and GOJO gives Clorox a larger B2B hygiene platform. The risk is that every new layer adds execution complexity. The same portfolio that gives the company diversification also forces management to allocate capital across retail categories, professional distribution, technology, debt, dividends and brand investment.

What gives Clorox a competitive advantage?

Clorox’s moat is not based on patents in the way a pharmaceutical company’s moat might be, and it is not a network effect like a digital platform. It is a consumer-staples moat built from brand trust, category leadership, product claims, retailer relationships, manufacturing and sourcing know-how, and repeat-purchase categories. The strongest proof point is the FY2025 disclosure that about 80% of sales came from brands holding No. 1 or No. 2 share positions in their categories.

Who are Clorox’s main competitors?

Competition varies by aisle. In cleaning and disinfecting, Clorox faces large branded competitors and retailer-owned private labels. In bags and wraps, branded trash-bag and food-storage companies compete with Glad and private labels. In cat litter, pet-care and store brands compete for repeat purchases. In food, Hidden Valley competes against branded dressings and retailer labels. In professional hygiene, the Purell platform moves Clorox into a B2B environment where distributor access, dispenser base and institutional trust matter. The FY2025 filing emphasizes that Clorox competes with multinational, national and private-label competitors, including companies with greater resources, which is why brand support and execution are not optional expenses.

What is the moat’s weak point?

The weak point is that the moat must be repurchased every year through brand spending, retail execution and price-value management. A household can switch to a private label if the perceived gap between price and performance becomes too wide. A retailer can allocate shelf space differently if velocity weakens. A supplier shock can compress gross margin before price changes catch up. That is why Clorox’s moat should be evaluated through volume, gross margin, advertising, customer concentration and segment EBIT, not through brand recognition alone.

Who owns Clorox stock, and why does governance matter now?

Clorox is a one-common-stock, institutionally influenced public company rather than a founder-controlled company. The latest 2025 proxy statement disclosed 121,683,474 shares outstanding at August 31, 2025. The largest disclosed holders were major index and asset-management institutions, while directors and executive officers as a group held less than 1%. That means governance pressure is more likely to come through board oversight, institutional voting, capital allocation discipline and performance incentives than through family or founder control.

Why does CEO succession matter in 2026?

Governance became more important after Clorox announced on May 28, 2026, that Chair and CEO Linda Rendle had asked the board to begin a comprehensive CEO search process for health reasons. The CEO search announcement stated that Rendle would remain chair and CEO during the process and until a successor is appointed, then serve in an advisory role. For investors, the timing matters because the successor will inherit GOJO integration, leverage management, ERP stabilization, gross-margin recovery and a refreshed operating agenda.

What opportunities and risks could change Clorox’s outlook?

The opportunity side is not just “sell more bleach.” The clearest company-specific upside comes from stabilizing ERP-related service levels, converting cost savings into margin recovery, integrating GOJO, keeping Glad economics attractive after the P&G arrangement ends, and protecting category share despite stressed consumers. The risk side is equally specific: debt-funded acquisition financing, retailer concentration, private label, raw-material volatility, cyber and systems execution, and the possibility that a new CEO changes priorities while the portfolio is already in transition.

How much could GOJO change the story?

Clorox completed the acquisition of GOJO Industries, maker of Purell, on April 1, 2026. The official transaction materials described a $2.25B cash transaction, expected tax benefits of about $330M, a net purchase price of about $1.92B, nearly $800M of annual GOJO sales, more than 80% of revenue through B2B distributors, an installed base of about 20M soap and sanitizer dispensers, and at least $50M of expected run-rate cost synergies. The acquisition is described in Clorox’s official GOJO completion announcement.

Which risks should researchers take seriously?

Which KPIs matter most for a Clorox DCF?

A Clorox DCF should focus less on one headline sales number and more on the drivers that convert household and professional demand into durable free cash flow. The most useful model variables are organic volume, price/mix, gross margin, advertising and promotion intensity, segment adjusted EBIT, capex, working capital, dividend capacity, leverage and acquisition synergies. These metrics explain whether the portfolio is defending its moat or borrowing from the future by over-discounting, under-investing, or taking on too much debt.

Why does the model matter for valuation?

The DCF logic is straightforward: revenue growth comes from category growth, volume, price/mix, acquisitions, divestitures and foreign exchange; operating profit depends on gross margin less advertising, selling, administrative and R&D expense; free cash flow equals operating cash flow minus capex; and equity value depends on how much cash remains after interest, tax, working capital, reinvestment, dividends, buybacks and debt reduction. Clorox’s own long-term IGNITE goals call for 3% to 5% net sales growth, 25 to 50 basis points of annual adjusted EBIT margin expansion, and free cash flow of 11% to 13% of net sales. Those targets are useful modeling anchors, not guaranteed outcomes.

What is the key takeaway from Clorox analysis?

Clorox is best understood as a high-recognition consumer-staples portfolio with a temporarily complicated operating and balance-sheet story. The company has valuable brands, repeat-purchase categories, a large U.S. retail base, professional-products optionality and a track record of returning cash. It also has real constraints: customer concentration, input-cost exposure, private-label competition, debt-funded acquisition financing, ERP normalization, CEO succession and the need to prove that GOJO can add more than complexity.